Grace Therapeutics (NASDAQ:GRCE) Earns Buy Rating from HC Wainwright

Grace Therapeutics (NASDAQ:GRCE – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 259.28% from the stock’s current price. Grace Therapeutics Stock Performance […]

Leave a Reply

Your email address will not be published.

Previous post Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Expected to Rise, HC Wainwright Analyst Says
Next post Canaccord Genuity Group Issues Positive Forecast for Sportradar Group (NASDAQ:SRAD) Stock Price